Loading
A phase 2 trial of Gemcitabine and Cisplatin in biliary tract cancer, run by Shanghai Guangsheng Biopharmaceutical Co., Ltd, now recruiting.
Cosiporfin Sodium for Injection Photodynamic Therapy is a phase 2 interventional study registered as NCT07398339 by Shanghai Guangsheng Biopharmaceutical Co., Ltd, with 30 participants planned, started 2026-03-31 and due to reach its primary completion in 2027-03-31. Interventions recorded: Cosiporfin Sodium for injection, DVDMS, Gemcitabine Hydrochloride for Injection and Cisplatin for injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cisplatin and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cisplatin and the tag pipeline.
Shares Gemcitabine, Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/